

University of Groningen

Pre-clinical investigation of brain mechanisms associated with Parkinson's disease: The impact of diet

Realí Nazario, Luiza

DOI:
[10.33612/diss.130756082](https://doi.org/10.33612/diss.130756082)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Realí Nazario, L. (2020). *Pre-clinical investigation of brain mechanisms associated with Parkinson's disease: The impact of diet*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.130756082>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

CHAPTER 2

Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches

Luiza Reali Nazario, Rosane S. da Silva, and Carla D. Bonan*

Laboratório de Neuroquímica e Psicofarmacologia, Departamento de Biologia Celular e Molecular, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

Edited by: Manuella P. Kaster, Universidade Federal de Santa Catarina, Brazil

Reviewed by: Mauricio Peña Cunha, Universidade Federal de Santa Catarina, Brazil;
Francisco Ciruela, University of Barcelona, Spain

*Correspondence: Carla D. Bonan cbonan@pucrs.br

This article was submitted and accepted to Neurodegeneration, a section of the journal Frontiers in Neuroscience

Front Neurosci. 2017; 11: 658.

Published online 2017 Nov 23. doi: 10.3389/fnins.2017.00658

PMCID: PMC5703841

PMID: 29217998



Abstract

Parkinson's disease (PD) is one of the most prevalent neurodegenerative disease displaying negative impacts on both the health and social ability of patients and considerable economical costs. The classical anti-parkinsonian drugs based in dopaminergic replacement are the standard treatment, but several motor side effects emerge during long-term use. This mini-review presents the rationale to several efforts from pre-clinical and clinical studies using adenosine receptor antagonists as a non-dopaminergic therapy. As several studies have indicated that the monotherapy with adenosine receptor antagonists reaches limited efficacy, the usage as a co-adjutant appeared to be a promising strategy. The formulation of multi-targeted drugs, using adenosine receptor antagonists and other neurotransmitter systems than the dopaminergic one as targets, have been receiving attention since Parkinson's disease presents a complex biological impact. While pharmacological approaches to cure or ameliorate the conditions of PD are the leading strategy in this area, emerging positive aspects have arisen from non-pharmacological approaches and adenosine function inhibition appears to improve both strategies.

Keywords: adenosine, A2AAR, dopaminergic system, neurodegeneration, Parkinson disease

General aspects of parkinson's disease

Parkinson's disease (PD) is the second most prevalent chronic neurodegenerative disease, affecting more than 1% of the elderly population, with diagnostic confirmation occurring when the loss of dopaminergic neurons in the striatum is close to 80% (de Rijk et al., 2000). PD is also diagnosed in people less than 40 years old, named early-onset PD (Crosiers et al., 2011). PD is associated with the formation of Lewy bodies and neurites (Braak et al., 2003), mainly composed of aggregated forms of α -synuclein (Spillantini et al., 1998). The loss of dopaminergic neurons causes a reduction in the release of dopamine, leading to motor symptoms such as bradykinesia, rigidity, imbalance and tremor (Jankovic, 2008). PD presents in sporadic and familial forms. The risk factors involved in the development of PD are both genetic and environmental (Mortimer et al., 2012; Noyce et al., 2012; Van der Mark et al., 2012; Pezzoli and Cereda, 2013). The familial form, with specific genetic targets, represents less than 10% of PD cases (Dawson and Dawson, 2010). The genetic aspects of the disease are linked to mutations in several genes related to a multitude of cellular mechanisms, such as protein aggregation, protein and membrane trafficking, lysosomal autophagy, immune response, synaptic function, endocytosis, inflammation, and metabolic pathways (Redenšek et al., 2017). The genes *SNCA* (PARK1), *UCHL1* (PARK5), *LRRK2* (PARK8), *GIGYF2* (PARK11), *OMI/HTRA2* (PARK13), *VPS35* (PARK17), and *EIF4G1* (PARK18) result in autosomal dominant PD, and *PRKN* (PARK2), *DJ-1* (PARK7), *ATP13A2* (PARK9), *PLA2G6* (PARK14), *FBX07* (PARK15), *DNJC6* (PARK19), and *SYNJ1* (PARK20) causes autosomal recessive PD (Lautier et al., 2008; Di Fonzo et al., 2009; Klein and Westenberger, 2012; Deng et al., 2015; Bartonikova et al., 2016; Miki et al., 2017; Scott et al., 2017). The gene contribution from other loci (PARK 3, 10, 12, and 16) is under investigation (Dawson and Dawson, 2010). However, a putative causative mutation in the gene that encodes the A₁ adenosine receptor, located in the locus PARK16, has been related to susceptibility to PD (Jaberi et al., 2016). Among the environmental contributors to PD development are occupational exposure of pesticides, such as Rotenone and Paraquat, infection by *Helicobacter* and HCV, low body weight and sedentary lifestyle (McCarthy et al., 2004; Villar-Cheda et al., 2009; Golabi et al., 2017; Sharma and Lewis, 2017; Shen et al., 2017).

The relationship of adenosine and dopamine signalling

Adenosine affects dopaminergic signaling through receptor heteromer formations and shared intracellular pathways. Adenosine is a neuromodulator that acts through the A₁ (A₁AR) and A₃ (A₃AR) inhibitory adenosine receptors and A_{2A} (A_{2A}AR) and A_{2B} (A_{2B}AR) excitatory adenosine receptors (Ralevic and Burnstock, 1998). D₁ (D₁DR) and D₂ (D₂DR) dopamine receptors are found co-localized with A_{2A}AR and A₁AR, mGluR₅ and NMDA (Hillion et al., 2002; Lee et al., 2002; Beggiato et al., 2016). The dopamine-adenosine receptor heteromers are constituted mainly of D₁DR/A₁AR and D₂DR/A_{2A}AR, displaying antagonistic properties. A₁AR agonist decreases the binding potential of dopamine to D₁DR, and reduces the D₁DR-induced cAMP production, while A₁AR antagonists activate D₁DR increasing cAMP levels (Ferré et al., 1998). A₃AR activation appears to have some influence on dopamine release and vesicular transport, while no functional impacts have been registered in dopamine receptors (Gołembiowska and Zylewska, 1998; Björklund et al., 2008; Shen et al., 2011).

The heteromerization of D₂DR/A_{2A}AR is one of the most studied receptors interaction. A_{2A}AR agonists reduce the *in vitro* affinity of the D₂DR agonist through an increase in D₂DR K_d without affecting receptor density (Ferré et al., 1991). *In vivo* studies confirmed these findings since the administration of A_{2A}AR antagonist increased the effects of the D₂DR agonist in the rat striatum and basal ganglia, while the action of A_{2A}AR agonists was opposite (Hillefors-Berglund et al., 1995; Strömberg et al., 2000). This heteromerization was confirmed through co-immunoprecipitation, fluorescence resonance energy, bioluminescence resonance energy transfer and *ex vivo* proximity ligation studies (Hillion et al., 2002; Canals et al., 2003; Trifilieff et al., 2011; Fernández-Dueñas et al., 2015). Studies with PET in the human brain showed the increased binding of a D₂DR antagonist, after the administration of caffeine, a nonselective antagonist of adenosine receptors (Volkow et al., 2015).

The interaction between adenosinergic and dopaminergic receptors has been described as intramembrane, involving direct interaction between receptors, or the modulation of G-proteins and the consequent influence on cAMP-dependent proteins (Fuxe et al., 1998; Ferré et al., 2001; Hillion et al., 2002; Fredholm and Svenningsson, 2003). The administration of D₂DR antagonists can reduce the cAMP production by A_{2A}AR and the D₂ agonist administration induces increase in cAMP

levels by A_{2A}AR (Vortherms and Watts, 2004; Botsakis et al., 2010). A_{2A}AR stimulation, *in vitro*, causes the phosphorylation and activation of DARPP-32, which can be inhibited by D₂DR activation (Nishi et al., 1997). A_{2A}AR antagonists increase D₂DR-dependent regulation of *c-fos*, which is more intense when dopaminergic neurodegeneration is presented (Pollack and Fink, 1995; Svenningsson et al., 1999). Compelling evidence for the impairment of D₂DR/A_{2A}AR oligomers in the striatum of rats was obtained in experimental Parkinsonism induced by 6-hydroxydopamine (6-OHDA) (Fernández-Dueñas et al., 2015). The ventral striopallidal GABA pathway appears to be a target of mGlu₅R/D₂DR/A_{2A}AR interactions. The co-administration of A_{2A}AR and mGlu₅R agonist enhances GABA release compared with mGlu₅R agonist alone, and this effect decreases with the administration of D₂DR agonists (Díaz-Cabiale et al., 2002). In addition, D₂DR/A_{2A}AR controls NMDA-mediated excitation in neurons from the nucleus accumbens through a direct protein–protein interaction (Azdad et al., 2009).

Support for the A_{2A}AR antagonism hypothesis from animal studies

The co-expression of D₂DR/A_{2A}AR receptors and their close functional and structural association in the striatopallidal GABAergic neurons reveals sites for therapeutic intervention and has received attention in the last three decades (Fink et al., 1992; Kase, 2001; Kelsey et al., 2009). The non-specific blockade of adenosine receptors by methylxanthines produces contralateral rotations in animals with dopaminergic lesions induced by 6-OHDA, since contralateral rotations have been related to an indirect stimulation of dopamine receptors in the lesioned area (Watanabe et al., 1981; Herrera-Marschitz et al., 1988).

During the late 1990s and early 2000s, exciting results from animal models of Parkinsonism indicated that A_{2A}AR antagonism improves motor activity by reducing the postsynaptic effects of dopamine depletion. Caffeine neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced lesion showed to be especially dependent on A_{2A}AR from the striatal neurons, but not exclusively (Chen et al., 2001; Xu et al., 2016). The A_{2A}AR antagonist KW6002 (Istradefylline) was shown to be powerful enough to increase locomotion activity and potentiate dopaminergic agonist motor effects in MPTP- and 6-OHDA-lesioned animals (Kanda et al., 1998, 2000; Grondin et al., 1999; Koga et al., 2000; Bibbiani et al., 2003). The anti-

parkinsonian effects of KW6002 and similar drugs, such as KW17837, appear to be dose-dependent, effective in the postsynapse and beyond the direct effect on the dopaminergic system, and act on glutamatergic/gabaergic neurotransmission and monoamine oxidase activity (Bibbiani et al., 2003; Petzer et al., 2003; Tanganelli et al., 2004; Orru et al., 2011). MSX-3, a water-soluble precursor of the highly specific A_{2A} AR antagonist MSX-2, which exhibits greater potency for A_{2A} AR than KW6002, appeared to be a candidate of monotherapy since it alleviates the symptomatic parkinsonian locomotor deficiency in a genetic model of dopaminergic degeneration (Yang et al., 2007; Marcellino et al., 2010).

While some studies advocated that A_{2A} AR antagonism, as a monotherapy, could reach a mildly lower or similar efficacy of L-DOPA treatment without inducing dyskinesia (Grondin et al., 1999; Pinna et al., 2007), the promisor effect of these drugs appeared to be when co-administrated with L-DOPA, simultaneously inhibiting A_{2A} AR and activating D_2 DR. A_{2A} AR-knockout animals demonstrated weak and transitory rotational sensitization and no sensitized grooming as a response to L-DOPA (Fredduzzi et al., 2002). The blockade of adenosine receptors by caffeine promoted additive or synergistic interactions with L-DOPA (Yu et al., 2006), whereas the co-administration of specific A_{2A} AR antagonists, such as KW6002, ST1535, and L-DOPA, potentiated the anti-parkinsonian effect of L-DOPA without exacerbating dyskinesia (Kanda et al., 2000; Koga et al., 2000; Bibbiani et al., 2003; Matsuya et al., 2007; Tronci et al., 2007). However, some studies using several A_{2A} AR antagonists, such as SCH4123-48, BIlB014 (Vipanedant), KW6002 and caffeine, when administered concomitantly and chronically with L-DOPA, failed to avoid dyskinesia (Jones et al., 2013).

The mechanism behind the effects of A_{2A} AR antagonists alone or as co-adjuvant drugs appears to beyond actions on dopaminergic system (Fuxe et al., 2009; Maggio et al., 2009; Figure Figure1).1). The A_{2A} AR exerts its neuronal activity in the striatum in a manner that is partially independent of D_2 Rs (Chen et al., 2001). Actually, KW6002 decreases the neuronal activity of the striatopallidal indirect pathway in the absence of D_2 R-mediated signaling (Aoyama et al., 2000). Dopaminergic neurodegeneration induced by transgenic mutant human α -synuclein is prevented in mice lacking the A_{2A} AR reinforcing the potential of shared downstream pathways (Ferraro et al., 2012). However, the adenylate cyclase activity did not differ in a genetic model of PD, suggesting that coupling to G-proteins of dopaminergic and

adenosinergic receptors should be a target (Botsakis et al., 2010). Regional differences appear in the anti-parkinsonian ability of $A_{2A}AR$ antagonism, since caffeine given at or before MPTP exposure blocks the nigral neurodegenerative process without restoring the striatal nerve terminal neurochemical features (Sonsalla et al., 2012). Motor sensitization developed in unilaterally 6-OHDA-lesioned rats submitted to L-DOPA has been associated with an overexpression of the GABA-synthesizing enzyme glutamic acid decarboxylase, dynorphin, and enkephalin mRNAs in the striatal efferent indirect pathway (Fink et al., 1992; Tronci et al., 2007). The impact of $A_{2A}AR$ antagonism over enkephalin content seems to promote motor recovery in D_2DR -knockout animals, but did not promote changes in the preproenkephalin mRNA in a 6-OHDA model (Fink et al., 1992; Aoyama et al., 2000). The functional relation of $D_2DR/A_{2A}AR$ in striatal medium spiny neurons appears to receive contributions of cholinergic signaling with consequences for the anti-tremor benefits of $A_{2A}AR$ antagonists (Simola et al., 2006; Tozzi et al., 2011; Salamone et al., 2013). The existence of $A_{2A}AR/mGlu_5R$ heteromers and shared intracellular cascades steps, such as the stimulation of DARPP32 phosphorylation, increase in cAMP levels and elevated *c-fos* expression, provides clues to the possible contribution of glutamatergic and adenosinergic signaling to the beneficial effects of adenosine receptor antagonism (Nash and Brotchie, 2000; Kachroo et al., 2005). Effects resembling akinesia in 6-OHDA-lesioned rats were fully reversed by either a single treatment of an $A_{2A}AR$ antagonist or an $mGlu_5R$ antagonist at higher doses, or by a combined treatment with ineffective doses of each compound (Coccurello et al., 2004). Increased $A_{2A}AR$ mRNA levels, decreased DARPP-32 phosphorylation and increased phosphorylation of ERK1/2 appeared in 6-OHDA-lesioned rats that display L-DOPA motor sensitization (Tomiya et al., 2004; Song et al., 2009). This altered downstream signaling pathway is recovered by CSC (8-(3-chlorostyryl) caffeine), an $A_{2A}AR$ antagonist (Song et al., 2009). Amelioration of motor response by $A_{2A}AR$ antagonism seems to be accompanied by the rescue of dopamine, dopamine metabolites, glutamate, and GABA striatal levels as well as the reversal of astroglial and microglial activation and antioxidant properties with beneficial outcomes on cognition (Aguiar et al., 2008; Gołembiowska et al., 2013; Uchida et al., 2014).




Figure 1: Schematic description of pharmacological and non-pharmacological strategies for PD management and its relation with adenosinergic signaling. Block of A_{2A}AR by antagonist induces reduction of positive effects over Adenyl cyclase and negative effects over D₂R signaling. Block of mGlu₅R reduces its positive effects over Adenyl cyclase through release of Ca²⁺. Recent studies with non-pharmacological strategies for PD have been related it with adenosine receptors expression.

Prodrugs such as DP-L-A2AANT were designed to conjugate the beneficial effects against dopaminergic degeneration obtained by the combined action of dopamine and A_{2A}AR antagonists in central nervous system (Dalpiaz et al., 2012). In addition to the potential dual action on adenosinergic and dopaminergic systems, the complimentary action on glutamatergic and adenosinergic systems appeared as prospective targets for dual anti-parkinsonian approaches. The combination of A_{2A}AR antagonists and NR2B or mGlu₅R antagonists has demonstrated attractive effects on motor activity with potential in the treatment of PD (Michel et al., 2014, 2015; Beggiato et al., 2016). A_{2A}AR–CB₁–D₂DR-receptor-heteromer has been suggested as a

component of motor alterations associated with dyskinesia and a possible target of multi-targeted drugs (Bonaventura et al., 2014; Pinna et al., 2014). The effects of caffeine-derived compounds over $A_{2A}AR$ and that of monoamine oxidase B have revealed that these proteins are targets for synergistic action with benefits on dopaminergic degeneration (Petzer and Petzer, 2015). Sulphonylphthalimides are also presented as a dual-targeted-direct compound acting in A_1AR and monoamine oxidase B (Van der Walt et al., 2015). The association of L-dopa, serotonin 5-HT $1A/1B$ receptor agonist and $A_{2A}AR$ antagonist also demonstrated a promissory strategy in 6-OHDA-lesioned rats exhibiting prevented or reduced dyskinetic-like behavior without impairing motor activity (Pinna et al., 2016).

Support for the $A_{2A}AR$ antagonism hypothesis from clinical tests

The $A_{2A}AR$ binding sites and mRNA levels in PD patients with dyskinesia are increased in striatopallidal pathway neurons in relation to healthy patients (Martinez-Mir et al., 1991; Calon et al., 2004). These data, in association with the experimental benefits of $A_{2A}AR$ antagonists in dopaminergic degenerative diseases increased the enthusiasm regarding non-dopaminergic drug development. Table 11 updates the clinical trials assigned in the EUA and European Union using adenosine receptor antagonists. Istradefylline had long-term tolerability and safety, including as an adjuvant therapy to levodopa (Hauser et al., 2003; Stacy et al., 2008). In 2008, US Food and Drug Administration issued a non-approvable letter to the use of Istradefylline in humans based in the concern if the efficacy findings support clinical utility of Istradefylline in patients with PD. However, Kyowa Hakko Kirin has received approval for the use of Istradefylline as adjunctive therapy in Japan (Dungo and Deeks, 2013; Mizuno et al., 2013). After the additional data request, a 12-week randomized study to evaluate oral Istradefylline in subjects with moderate to severe PD ended with disappointing results, since Istradefylline did not change the off time per day (NCT01968031). However, a clinical trial is currently open (NCT02610231). Preladenant was evaluated as monotherapy to patients with early PD since it reduced the mean daily off time in a phase II study; however, no evidence has supported its efficacy in phase III studies (Hauser, 2011; Stocchi et al., 2017). BIIB014 and SCH900800 also failed to prove efficacy in clinical trials, while Tozadenant showed a mean daily off time reduction accompanied by adverse events of dyskinesia, nausea,

and dizziness (Hauser et al., 2014). A safety and efficacy study of Tozadenant to treat end of dose wearing off in PD patients using L-DOPA is currently open (NCT02453386). Multiple epidemiological studies indicate that caffeine is able to prevent PD development (Ross et al., 2000; Ascherio et al., 2001). In a pilot study of caffeine for daytime sleepiness in PD, there was evident benefit on the motor manifestations of disease with no adverse effects (Postuma et al., 2012). Recently, a clinical trial has aimed to evaluate the efficacy of caffeine for motor and non-motor aspects of disease (NCT01738178). Nowadays, changing the dose and frequency of daily drug taking had no benefits in the use of adenosine receptor antagonists as a monotherapy or as an adjuvant of current Parkinsonism treatment.

Drug	Sponsor	Identifier number (year)	Parkinson's disease patient condition	Outcome measures (dose tested)	Phase	Status	Results
Istradefylline (KW6002)	Kyowa Hakko Kirin Co., Ltd	NCT02610231* (2015)	Moderate to severe disease	Safety and tolerability (20 or 40 mg oral daily)	III	Active – not recruiting	-
		NCT01968031* (2013) 2013-002254-70** (2014)	Moderate to Severe Disease	Efficacy and safety (20 or 40 mg daily)	III	Completed	No change in the OFF time
		NCT00957203* (2009)	Advanced disease treated with levodopa	Long-term safety and efficacy (20 or 40 mg daily)	III	Completed	
		NCT00955526* (2009)	Levodopa-Treated	Efficacy in reducing the mean total hours of awake time per day spent in the OFF state (20 or 40 mg daily)	III	Completed	Reduction in daily OFF time
		NCT00456794* (2007)	Advanced disease treated with levodopa/carbidopa	Safety and efficacy compared with placebo in subjects with OFF-time (20 and 60 mg daily)	II	Completed	Significant reduction in OFF time, and was well tolerated as adjunctive treatment to levodopa
		NCT00456586* (2007)	Advanced disease treated with levodopa/carbidopa	Safety and efficacy compared with placebo in subjects with OFF phenomena(40 mg daily)	II	Completed	Istradefylline was safe, well toler-ated, and effective at improving end-of-dose wearing
		NCT00455507* (2007)	Advanced disease treated with levodopa.	Efficacy for reducing the mean total hours of awake time per day spent in the OFF state(20 or 40 mg daily)	II	Completed	
		2004-002844-93** (2005)	Motor response complications on levodopa therapy	Long-term tolerability and safety (20 or 40 mg daily)	III	Completed	Istradefylline was well tolerated as adjunctive therapy to levodopa for subjects with Parkinson's disease
		NCT00250393* (2005)	Not specified	Change in Unified Parkinson's Disease Rating Scale (UPDRS) part-III (Motor examination) (40 mg daily)	II	Completed	
		NCT00203957* (2005)	Motor Response Complications on Levodopa	Confirmation of long term tolerability and safety (20 or 40 mg daily)	III	Completed	
		NCT00199420* (2005)	Aadvanced disease treated with levodopa	Percentage of OFF time (10, 20 or 40 mg daily)	III	Completed	

Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches |

		NCT00199407* (2005)	Advanced disease treated with levodopa	Efficacy for reducing the percentage of OFF time (20 mg daily)	III	Completed	
		NCT00199394* (2005)	Advanced disease treated with levodopa	Percentage of awake time spent in the OFF state (40 mg daily)	III	Completed	
		NCT00199381* (2005)	Patients Who Have Recently Completed One Year of Treatment With Istradefylline	Long-term tolerability and safety (20 or 40 mg daily)	III	Completed	The Sponsor decided to terminate the study early (not for safety reasons)
		NCT00199368* (2005)	Patients With Motor Response Complications on Levodopa Therapy, who have completed prior istradefylline studies	Safety Study (20 or 40 mg daily)	III	Completed	
		NCT00199355* (2005)	Advanced disease treated with levodopa /DCI.	OFF time (20 or 40 mg daily)	II		
	NINDS	NCT00006337* (2000)	Not specified	Effects on symptoms and dyskinesias	II	Completed	
SCH900800	Merck Sharp & Dohme Corp.	NCT01500707* (2011)	Moderate to Severe Disease treated with Levodopa	Pharmacokinetics of SCH 900800 (20 mg daily)	I	Study withdrawn	-
Preladenant (SCH 420814)	Merck Sharp & Dohme Corp.	NCT01294800* (2011)	Moderate to severe disease experiencing motor fluctuations and receiving levodopa	Efficacy on "off" time (2, 5, 10 mg twice/day)	II	Completed	Change From Baseline in Mean "Off" Time
		NCT01227265* (2010)	Moderate to severe disease	Efficacy and safety (2-5 mg twice/day)	III	Completed	Not superior to placebo in reducing off time from baseline
		NCT01155479* (2010)	Early Parkinson's disease	Efficacy and safety (2,5, 10 mg twice/day)	III	Completed	Change From Baseline in motor impairments and disability
		2009-015161-31** (2010)	Moderate to severe disease	Efficacy and Safety (2,5, 10 mg twice/day)	III	Completed	
		2009-015162-57** (2010)	Moderate to severe disease	Extension Study (2,5, 10 mg twice/day)	III	Study withdrawn	Lack of efficacy in the parent studies.
		NCT01155466* (2010)	Moderate to severe disease	Stability in levodopa dose (2, 5, 10 mg twice/day)	III	Completed	No change From Baseline in Mean "Off" Time
		2009-013552-72** (2010)	Early Parkinson's disease	Dose-Range-Finding Efficacy and Safety (2, 5, or 10 mg twice/day)	III	Completed	No statistically significant or clinically meaningful difference vs. placebo
		NCT01215227* (2010)	Moderate to severe disease	Long-term safety and tolerability from patients of NCT01155466 and NCT01227265 (2, 5, 10 mg twice/day)			Terminated early due to the lack of efficacy in the parent studies NCT1155466 and NCT01227265.
		NCT00845000* (2009)	Levodopa treated	Effects on the dyskinesia and antiparkinsonian actions of a levodopa infusion (10 or 100 mg daily)	I	Completed	
		NCT00537017* (2007)	Moderate to severe disease	Long term safety (5 mg twice daily)	II	Completed	Long-term preladenant treatment (5 mg twice a day) was well tolerated and provided sustained OFF time reductions

							and ON time increases
		NCT00406029* (2006)	Not specified	Efficacy and safety when used together with a stable dose of L-dopa/dopa decarboxylase (1, 2, 5 and 10 mg twice a day)	II	Completed	Mean daily off time reduced (5 mg and 10 mg)
Tozadenant (SYN115)	Biotie Therapies Inc.	NCT03051607* 2016-003961-25** (2017)	Experiencing end of dose "Wearing-Off"	Safety and Tolerability(120 mg oral twice daily)	III	Recruiting	-
		2014-005630-60** (2015)	Levodopa-Treated Experiencing End-of-Dose "Wearing-Off"	Efficacy and Safety as Adjunctive Therapy to Levodopa (60 mg oral daily)	III	Active	-
		2011-005054-59** (2013)	Experiencing end of dose "Wearing-Off"	Safety and efficacy as an adjunct to levodopa (60 mg oral daily)	II	Completed	
		NCT01283594* (2011)	Motor fluctuations on levodopa	Safety and efficacy as an adjunct to levodopa(60, 120, 180, 240 mg twice/day)	II/III	Completed	Tozadenant (120 or 180 mg) was generally well tolerated and was effective at reducing off-time.
BIIB014	Oxford BioMedica	NCT00627588* (2008)	Early Parkinson's disease	Safety, Efficacy and Dose Evaluation	I/II	Completed	
Caffeine	McGill University Health Center	NCT01738178* (2012)	Not specified	Motor effects of caffeine persist (or even magnify)helps reduce dose of other PD meds and/or prevents their side effects (200 mg daily)	III	Completed	-
	Ron Postuma	NCT01190735* (2010)	Not specified	Optimal caffeine dose with maximal motor benefit and the least amount of undesirable adverse effects (100-200 mg twice/day)	II	Completed	
		NCT00459420* (2007)	Not specified	Effect on sleepiness and motor symptoms (100-200 mg daily)	II/III	Completed	No significant benefit on excessive daytime sleepiness

Table 1

A_{2A}AR antagonists under clinical investigation for Parkinson's disease.

*ClinicalTrials.gov

**EU Clinical Trials Register.

Association of A_{2A}AR antagonism and non-pharmacological approaches

Non-pharmacological approaches are strategies to combine, reinforce and complement the pharmacological options for the management and prevention of PD (Figure (Figure1).1). Dance, treadmill and aquatic exercises feasibility to PD management have been evaluated in clinical trials with benefits to life quality, based in cognitive and motor features (Picelli et al., 2016; Carroll et al., 2017; Shanahan et al., 2017). Recently, it was demonstrated that treadmill exercises induce brain

activation in PD (Maidan et al., 2017). These benefits have been reproduced in animal models of PD suggesting that physical exercise prevents the development of L-DOPA-induced dyskinesia and its association with hyperphosphorylation of DARPP-32, c-Fos expression and increased brain-derived neurotrophic factor (BDNF) levels (Gyárfás et al., 2010; Aguiar et al., 2013; Shin et al., 2017). Studies with wheel running rats revealed that A₁AR and A_{2A}AR expression is reduced in the striatum, reinforcing the idea that physical exercise is able to promote neuroplasticity and neuroprotection to brain regions related to motor control, probably through the reduction of antagonistic adenosine effects over dopamine signaling (Clark et al., 2014).

Deep Brain Stimulation (DBS) was approved by the FDA in 2002 as therapy for advanced PD (Suarez-Cedeno et al., 2017). From studies with animals, DBS appeared to have a neuroprotective effect against loss of dopaminergic neurons induced by classical dopaminergic neurotoxins (Maesawa et al., 2004). The use of A_{2A}AR antagonism as an adjuvant of DBS in rodents suggests the potential to enhance the response in the treatment of parkinsonian symptoms, such as tremor (Collins-Praino et al., 2013). While clinical studies using transcranial direct current stimulation (tDCS) in PD suggest possible locomotor benefits, the biological mechanism is still under investigation (Benninger et al., 2011). In rodents, tDCS on the cerebral cortex promotes cognitive effects involving A₁AR, although the adenosinergic participation in tDCS responses of PD has not been evaluated (Márquez-Ruiz et al., 2012). Electroconvulsive therapy (ECT) has been proposed to be efficient for both motor and non-motor symptoms in PD with psychological problems (Nishioka et al., 2014; Calderón-Fajardo et al., 2015). The proposed mechanism for ECT includes the enhancement of dopaminergic transmission in the striatum and an increase in the levels of levodopa by disrupting the blood–brain barrier (Kennedy et al., 2003). The purinergic system appears to be influenced by ECT, since the action, metabolism and release of nucleotide and nucleoside are altered under ECT, but no correlation with PD was identified until now (Gleiter et al., 1989; Busnello et al., 2008; Sadek et al., 2011). A combination of drugs and non-pharmacological therapies could warrant new investigations into the preclinical and clinical studies, with hope for the amelioration and affects in PD prevention, management and treatment.

Conclusions

This review highlights the need to intensify research into adenosine signaling in the development of PD therapies. The interaction between adenosine and dopamine signaling has been extensively studied and contributed to knowledge of the role of non-dopaminergic neurotransmitters in the PD. As cholinergic, glutamatergic, GABAergic, cannabinergic and serotonergic systems appear together with adenosinergic system in the myriad of pathways involved in the PD, appearing together with the possibility of improved results from dual or multi-targeted anti-parkinsonism approaches opened a new area of drug development. In addition, the association of pharmacological and non-pharmacological approaches brings new perspectives for a more effective treatment of PD and improved of quality of life for PD patients.

Author contributions

LN, RdS, and CB equally contributed to the definition of the scope and to the writing of the manuscript.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

LN is a recipient of Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)/PROEX fellowship.

Glossary

Abbreviations

A ₁ AR	A ₁ adenosine receptor
A _{2A} AR	A _{2A} adenosine receptor
A _{2B} AR	A _{2B} adenosine receptor

A ₃ AR	A ₃ adenosine receptor
BDNF	brain-derived neurotrophic factor
DARPP-32	Dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa
D ₁ DR	D ₁ dopamine receptor
D ₂ DR	D ₂ dopamine receptor
PD	Parkinson's disease
6-OHDA	6-hydroxydopamine
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Footnotes

Funding. RdS is a Research Career Awardees of the CNPq/Brazil (Proc: 301599/2016-5). CB is a Research Career Awardees of the CNPq/Brazil (Proc 305035/2015-0).

References

1. Aguiar A. S., Jr., Moreira E. L., Hoeller A. A., Oliveira P. A., Córdova F. M., Glaser V., et al. . (2013). Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice. *Neuroscience* 243, 46–53. 10.1016/j.neuroscience.2013.03.039
2. Aguiar L. M., Macêdo D. S., Vasconcelos S. M., Oliveira A. A., de Sousa F. C., Viana G. S. (2008). CSC, an adenosine A_{2A} receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats. *Brain Res.* 1191, 192–199. 10.1016/j.brainres.2007.11.051
3. Aoyama S., Kase H., Borrelli E. (2000). Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A_{2A} receptor antagonist. *J. Neurosci.* 20, 5848–5852.
4. Ascherio A., Zhang S. M., Hernán M. A., Kawachi I., Colditz G. A., Speizer F. E., et al. . (2001). Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. *Ann. Neurol.* 50, 56–63. 10.1002/ana.1052
5. Azdad K., Gall D., Woods A. S., Ledent C., Ferré S., Schiffmann S. N. (2009). Dopamine D₂ and adenosine A_{2A} receptors regulate NMDA-mediated excitation in accumbens neurons through A_{2A}-D₂ receptor heteromerization. *Neuropsychopharmacology* 34, 972–986. 10.1038/npp.2008.144
6. Bartonikova T., Mensikova K., Mikulicova L., Vodicka R., Vrtel R., Godava M., et al. . (2016). Familial atypical parkinsonism with rare variant in VPS35 and FBXO7 genes: a case report. *Medicine (Baltimore)* 95:e5398. 10.1097/MD.00000000000005398
7. Beggiato S., Tomasini M. C., Borelli A. C., Borroto-Escuela D. O., Fuxe K., Antonelli T., et al. . (2016). Functional role of striatal A_{2A}, D₂, and mGlu5 receptor interactions in regulating striatopallidal GABA neuronal transmission. *J. Neurochem.* 138, 254–264. 10.1111/jnc.13652
8. Benninger D. H., Lomarev M., Lopez G., Pal N., Luckenbaugh D. A., Hallett M. (2011). Transcranial direct current stimulation for the treatment of focal hand dystonia. *Mov. Disord.* 26, 1698–1702. 10.1002/mds.
9. Bibbiani F., Oh J. D., Petzer J. P., Castagnoli N., Jr., Chen J. F., Schwarzschild M. A., et al. . (2003). A_{2A} antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. *Exp. Neurol.* 184, 285–294. 10.1016/S0014-4886(03)00250-4
10. Björklund O., Halldner-Henriksson L., Yang J., Eriksson T. M., Jacobson M. A., Daré E., et al. . (2008). Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice. *Physiol. Behav.* 95, 668–676. 10.1016/j.physbeh.2008.09.018
11. Bonaventura J., Rico A. J., Moreno E., Sierra S., Sánchez M., Luquin N., et al. (2014). L-DOPA-treatment in primates disrupts the expression of A_{2A} adenosine-CB₁ cannabinoid-D₂ dopamine receptor heteromers in the caudate nucleus. *Neuropharm.* 79, 90–100. 10.1016/j.neuropharm.2013.10.036
12. Botsakis K., Pavlou O., Poulou P. D., Matsokis N., Angelatou F. (2010). Blockade of adenosine A_{2A} receptors downregulates DARPP-32 but increases ERK1/2 activity in striatum of dopamine deficient “weaver” mouse. *Neurochem. Int.* 56, 245–249. 10.1016/j.neuint.2009.10.007
13. Braak H., Rüb U., Gai W. P., Del Tredici K. (2003). Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion

- by an unknown pathogen. *J. Neural Transm. (Vienna)* 110, 517–536. 10.1007/s00702-002-0808-2
14. Busnello J. V., Oses J. P., da Silva R. S., Feier G., Barichello T., Quevedo J., et al. . (2008). Peripheral nucleotide hydrolysis in rats submitted to a model of electroconvulsive therapy. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 32, 1829–1833. 10.1016/j.pnpbp.2008.08.007
15. Calderón-Fajardo H., Cervantes-Arriaga A., Llorens-Arenas R., Ramírez-Bermudez J., Ruiz-Chow Á., Rodríguez-Violante M. (2015). Electroconvulsive therapy in Parkinson's disease. *Arq Neuropsiquiatr.* 73, 856–860. 10.1590/0004-282X20150131
16. Calon F., Dridi M., Hornykiewicz O., Bédard P. J., Rajput A. H., Di Paolo T. (2004). Increased adenosine A_{2A} receptors in the brain of Parkinson's disease patients with dyskinesias. *Brain* 127(Pt 5), 1075–1084. 10.1093/brain/awh128
17. Canals M., Marcellino D., Fanelli F., Ciruela F., de Benedetti P., Goldberg S. R., et al. . (2003). Adenosine A_{2A}-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. *J. Biol. Chem.* 278, 46741–46749. 10.1074/jbc.M306451200
18. Carroll L. M., Volpe D., Morris M. E., Saunders J., Clifford A. M. (2017). Aquatic exercise therapy for people with Parkinson disease: a randomized controlled trial. *Arch. Phys. Med. Rehabil.* 98, 631–638. 10.1016/j.apmr.2016.12.006
19. Chen J. F., Xu K., Petzer J. P., Staal R., Xu Y. H., Beilstein M., et al. (2001). Neuroprotection by caffeine and A_{2A} adenosine receptor inactivation in a model of Parkinson's disease. *J. Neurosci.* 21:RC143.
20. Clark P. J., Ghasem P. R., Mika A., Day H. E., Herrera J. J., Greenwood B. N., et al. . (2014). Wheel running alters patterns of uncontrollable stress-induced cfos mRNA expression in rat dorsal striatum direct and indirect pathways: a possible role for plasticity in adenosine receptors. *Behav. Brain Res.* 272, 252–263. 10.1016/j.bbr.2014.07.006
21. Coccurello R., Breyse N., Amalric M. (2004). Simultaneous blockade of adenosine A_{2A} and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. *Neuropsychopharmacology* 29, 1451–1461. 10.1038/sj.npp.1300444
22. Collins-Praino L. E., Paul N. E., Ledgard F., Podurgiel S. J., Kovner R., Baqi Y., et al. . (2013). Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A_{2A} antagonism. *Eur. J. Neurosci.* 38, 2183–2191. 10.1111/ejn.12212
23. Crosiers D., Theuns J., Cras P., Van Broeckhoven C. (2011). Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. *J. Chem. Neuroanat.* 42, 131–141. 10.1016/j.jchemneu.2011.07.003
24. Dalpiaz A., Cacciari B., Vicentini C. B., Bortolotti F., Spalluto G., Federico S., et al. . (2012). A novel conjugated agent between dopamine and an A_{2A} adenosine receptor antagonist as a potential anti-Parkinson multitarget approach. *Mol. Pharm.* 9, 591–604. 10.1021/mp200489d
25. Dawson T., Dawson V. L. (2010). The role of Parkin in Familial and Sporadic Parkinson's Disease. *Mov. Disord.* 25, S32–S39. 10.1002/mds.22798
26. Deng S., Deng X., Yuan L., Song Z., Yang Z., Xiong W., et al. . (2015). Genetic analysis of SNCA coding mutation in Chinese Han patients with Parkinson disease. *Acta Neurol. Belg.* 115, 267–271. 10.1007/s13760-014-0347-2
27. de Rijk M. C., Launer L. J., Berger K., Breteler M. M., Dartigues J. F., Baldereschi M., et al. . (2000). Prevalence of Parkinson's disease in Europe: a collaborative study

- of population-based cohorts. *Neurology* 54(11 Suppl. 5), S21–S23. 10.1212/WNL.54.11.21A
28. Díaz-Cabiale Z., Vivó M., Del Arco A., O'Connor W. T., Harte M. K., Müller C. E., et al. (2002). Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A_{2A} and dopamine D₂ receptors. *Neurosci. Lett.* 324, 154–158. 10.1016/S0304-3940(02)00179-9
29. Di Fonzo A., Fabrizio E., Thomas A., Fincati E., Marconi R., Tinazzi M., et al. (2009). GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. *Parkinsonism Relat. Disord.* 15, 703–705. 10.1016/j.parkreldis.2009.05.001
30. Duno R., Deeks E. D. (2013). Istradefylline: first global approval. *Drugs* 73, 875–882. 10.1007/s40265-013-0066-7
31. Fernández-Dueñas V., Taura J. J., Cottet M., Gómez-Soler M., López-Cano M., Ledent C., et al. . (2015). Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats. *Dis. Model. Mech.* 8, 57–63. 10.1242/dmm.018143
32. Ferré S., Popoli P., Giménez-Llort L., Rimondini R., Müller C. E., Strömberg I., et al. . (2001). Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. *Parkinsonism Relat. Disord.* 7, 235–241. 10.1016/S1353-8020(00)00063-8
33. Ferré S., Torvinen M., Antoniou K., Irenius E., Civelli O., Arenas E., et al. . (1998). Adenosine A₁ receptor-mediated modulation of dopamine D₁ receptors in stably cotransfected fibroblast cells. *J. Biol. Chem.* 273, 4718–4724. 10.1074/jbc.273.8.4718
34. Ferré S., von Euler G., Johansson B., Fredholm B. B., Fuxe K. (1991). Stimulation of high affinity adenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. *Proc. Natl. Acad. Sci. U.S.A.* 88, 7238–7241 10.1073/pnas.88.16.7238
35. Ferraro L., Beggiato S., Tomasini M. C., Fuxe K., Antonelli T., Tanganelli S. (2012). A_{2A}/D₂ receptor heteromerization in a model of Parkinson's disease. Focus on striatal aminoacidergic signaling. *Brain Res.* 1476, 96–107. 10.1016/j.brainres.2012.01.032
36. Fink J. S., Weaver D. R., Rivkees S. A., Peterfreund R. A., Pollack A. E., Adler E. M., et al. . (1992). Molecular cloning of the rat A₂ adenosine receptor: selective co-expression with D₂ dopamine receptors in rat striatum. *Brain Res. Mol. Brain Res.* 14, 186–195. 10.1016/0169-328X(92)90173-9
37. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., et al. . (2002). Persistent behavioral sensitization to chronic L-DOPA requires A_{2A} adenosine receptors. *J. Neurosci.* 22, 1054–1062.
38. Fredholm B. B., Svenningsson P. (2003). Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. *Neurology* 61(11 Suppl. 6), S5–S9. 10.1212/01.WNL.0000095204.89871.FF
39. Fuxe K., Ferré S., Zoli M., Agnati L. F. (1998). Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A_{2A}/dopamine D₂ and adenosine A₁/dopamine D₁ receptor interactions in the basal ganglia. *Brain Res. Brain Res. Rev.* 26, 258–273. 10.1016/S0165-0173(97)00049-0
40. Fuxe K., Marcellino D., Guidolin D., Woods A. S., Agnati L. (2009). Brain receptor mosaics and their intramembrane receptor-receptor interactions: molecular

- integration in transmission and novel targets for drug development. J. Acupunct. Meridian Stud. 2, 1–25. 10.1016/S2005-2901(09)60011-X
41. Gleiter C. H., Deckert J., Nutt D. J., Marangos P. J. (1989). Electroconvulsive shock (ECS) and the adenosine neuromodulatory system: effect of single and repeated ECS on the adenosine A1 and A2 receptors, adenylyl cyclase, and the adenosine uptake site. J. Neurochem. 52, 641–646. 10.1111/j.1471-4159.1989.tb09168.x
 42. Golabi P., Otgonsuren M., Sayiner M., Arsalla A., Gogoll T., Younossi Z. M. (2017). The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection. Ann. Hepatol. 16, 342–348. 10.5604/01.3001.0009.8588
 43. Gołombiowska K., Wardas J., Noworyta-Sokołowska K., Kaminska K., Górská A. (2013). Effects of adenosine receptor antagonists on the *in vivo* LPS-induced inflammation model of Parkinson's disease. Neurotox. Res. 24, 29–40. 10.1007/s12640-012-9372-1
 44. Gołombiowska K., Zylewska A. (1998). N6-2-(4-aminophenyl)ethyladenosine (APNEA), a putative adenosine A3 receptor agonist, enhances methamphetamine-induced dopamine outflow in rat striatum. Pol. J. Pharmacol. 50, 299–305.
 45. Grondin R., Bédard P. J., Hadj T. A., Grégoire L., Mori A., Kase H. (1999). Antiparkinsonian effect of a new selective adenosine A_{2A} receptor antagonist in MPTP-treated monkeys. Neurology 52, 1673–1677. 10.1212/WNL.52.8.1673
 46. Gyárfás T., Knuuttila J., Lindholm P., Rantamäki T., Castrén E. (2010). Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy *in vivo*. Cell. Mol. Neurobiol. 30, 361–368. 10.1007/s10571-009-9458-3
 47. Hauser R. A. (2011). Future treatments for Parkinson's disease: surfing the PD pipeline. Int. J. Neurosci. 121, 53–62. 10.3109/00207454.2011.620195
 48. Hauser R. A., Hubble J. P., Truong D. D., Istradefylline US-001 Study Group (2003). Randomized trial of the adenosine A_{2A} receptor antagonist istradefylline in advanced PD. Neurology 61, 297–303. 10.1212/01.WNL.0000081227.84197.0B
 49. Hauser R. A., Olanow C. W., Kieburtz K. D., Pourcher E., Docu-Axelerad A., Lew M., et al. . (2014). Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised Trial. Lancet Neurol. 13, 767–776. 10.1016/S1474-4422(14)70148-6
 50. Herrera-Marschitz M., Casas M., Ungerstedt U. (1988). Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses. Psychopharmacology (Berl) 94, 38–45. 10.1007/BF00735878
 51. Hillefors-Berglund M., Liu Y., von Euler G. (1995). Persistent, specific and dose-dependent effects of toluene exposure on dopamine D2 agonist binding in the rat caudate-putamen. Toxicology 100, 185–194. 10.1016/0300-483X(95)03084-S
 52. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., et al. . (2002). Coaggregation, cointernalization, and codesensitization of adenosine A_{2A} receptors and dopamine D2 receptors. J. Biol. Chem. 277, 18091–18097. 10.1074/jbc.M107731200
 53. Jaber E., Rohani M., Shahidi G. A., Nafissi S., Arefian E., Soleimani M., et al. . (2016). Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction. Mov. Disord. 31, 1004–1011. 10.1002/mds.26627
 54. Jankovic J. (2008). Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr. 79, 368–376. 10.1136/jnnp.2007.131045

55. Jones N., Bleickardt C., Mullins D., Parker E., Hodgson R. (2013). A_{2A} receptor antagonists do not induce dyskinesias in drug-naïve or L-dopa sensitized rats. *Brain Res. Bull.* 98, 163–169. 10.1016/j.brainresbull.2013.07.001
56. Kachroo A., Orlando L. R., Grandy D. K., Chen J. F., Young A. B., Schwarzschild M. A. (2005). Interactions between metabotropic glutamate 5 and adenosine A_{2A} receptors in normal and parkinsonian mice. *J. Neurosci.* 25, 10414–10419. 10.1523/JNEUROSCI.3660-05.2005
57. Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H., et al. (2000). Combined use of the adenosine A_{2A} antagonist KW-6002 with L-DOPA or with selective D₁ or D₂ dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. *Exp. Neurol.* 162, 321–327. 10.1006/exnr.2000.7350
58. Kanda T., Tashiro T., Kuwana Y., Jenner P. (1998). Adenosine A_{2A} receptors modify motor function in MPTP-treated common marmosets. *Neuroreport.* 9, 2857–2860. 10.1097/00001756-199808240-00032
59. Kase H. (2001). New aspects of physiological and pathophysiological functions of adenosine A_{2A} receptor in basal ganglia. *Biosci. Biotechnol. Biochem.* 65, 1447–1457. 10.1271/bbb.65.1447
60. Kennedy P., Evans M. J., Berry C., Mullin J. (2003). Comparative analysis of goal achievement during rehabilitation for older and younger adults with spinal cord injury. *Spinal Cord.* 41, 44–52. 10.1038/sj.sc.3101386
61. Kelsey J. E., Langelier N. A., Oriel B. S., Reedy C. (2009). The effects of systemic, intrastratial, and intrapallidal injections of caffeine and systemic injections of A_{2A} and A₁ antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat. *Psychopharmacology (Berl)* 201, 529–539. 10.1007/s00213-008-1319-0
62. Klein C., Westenberger A. (2012). Genetics of Parkinson's disease. *Cold Spring Harb. Perspect. Med.* 2:a008888. 10.1101/cshperspect.a008888
63. Koga K., Kurokawa M., Ochi M., Nakamura J., Kuwana Y. (2000). Adenosine A_{2A} receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. *Eur. J. Pharmacol.* 408, 249–255. 10.1016/S0014-2999(00)00745-7
64. Lautier C., Goldwurm S., Dürr A., Giovannone B., Tsiaras W. G., Pezzoli G., et al. . (2008). Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. *Am. J. Hum. Genet.* 82, 822–833. 10.1016/j.ajhg.2008.01.015
65. Lee F. J., Xue S., Pei L., Vukusic B., Chéry N., Wang Y., et al. . (2002). Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. *Cell* 111, 219–230. 10.1016/S0092-8674(02)00962-5
66. Maesawa S., Kaneoke Y., Kajita Y., Usui N., Misawa N., Nakayama A., et al. . (2004). Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. *J. Neurosurg.* 100, 679–687. 10.3171/jns.2004.100.4.0679
67. Maggio R., Aloisi G., Silvano E., Rossi M., Millan M. J. (2009). Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance. *Parkinsonism Relat. Disord.* 15, S2–7. 10.1016/S1353-8020(09)70826-0
68. Maidan I., Rosenberg-Katz K., Jacob Y., Giladi N., Hausdorff J. M., Mirelman A. (2017). Disparate effects of training on brain activation in Parkinson disease. *Neurology* 89, 1804–1810. 10.1212/WNL.0000000000004576
69. Marcellino D., Lindqvist E., Schneider M., Müller C. E., Fuxe K., Olson L., et al. . (2010). Chronic A_{2A} antagonist treatment alleviates parkinsonian locomotor

- deficiency in MitoPark mice. *Neurobiol. Dis.* 40, 460–466. 10.1016/j.nbd.2010.07.008
70. Márquez-Ruiz J., Leal-Campanario R., Sánchez-Campusano R., Molaei-Ardekani B., Wendling F., Miranda P. C., et al. . (2012). Transcranial direct-current stimulation modulates synaptic mechanisms involved in associative learning in behaving rabbits. *Proc. Natl. Acad. Sci. U.S.A.* 109, 6710–6715. 10.1073/pnas.1121147109
71. Martinez-Mir M. I., Probst A., Palacios J. M., Adenosine A. (1991). Receptors: selective localization in the human basal ganglia and alterations with disease. *Neuroscience* 42, 697–706. 10.1016/0306-4522(91)90038-P
72. Matsuya T., Takuma K., Sato K., Asai M., Murakami Y., Miyoshi S., et al. . (2007). Synergistic effects of adenosine A_{2A} antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. *Pharmacol Sci.* 103, 329–332. 10.1254/jphs.SCZ070058
73. McCarthy S., Somayajulu M., Sikorska M., Borowy-Borowski H., Pandey S. (2004). Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. *Toxicol. Appl. Pharmacol.* 201, 21–31. 10.1016/j.taap.2004.04.019
74. Michel A., Downey P., Nicolas J. M., Scheller D. (2014). Unprecedented therapeutic potential with a combination of A_{2A}/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease. *PLoS ONE* 9:e114086. 10.1371/journal.pone.0114086
75. Michel A., Downey P., Van Damme X., De Wolf C., Schwarting R., Scheller D. (2015). Behavioural Assessment of the A_{2A}/NR2B combination in the unilateral 6-OHDA-lesioned rat model: a new method to examine the therapeutic potential of non-dopaminergic drugs. *PLoS ONE* 10:e0135949. 10.1371/journal.pone.0135949
76. Miki Y., Tanji K., Mori F., Kakita A., Takahashi H., Wakabayashi K. (2017). PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease. *Neurosci. Lett.* 645, 40–45. 10.1016/j.neulet.2017.02.027
77. Mizuno Y., Kondo T., Japanese Istradefylline Study Group (2013). Adenosine A_{2A} receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. *Mov. Disord.* 28, 1138–1141. 10.1002/mds.25418
78. Mortimer J. A., Borenstein A. R., Nelson L. M. (2012). Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. *Neurology* 79, 1174–1180. 10.1212/WNL.0b013e3182698ced
79. Nash J. E., Brotchie J. M. (2000). A common signaling pathway for striatal NMDA and adenosine A_{2A} receptors: implications for the treatment of Parkinson's disease. *J. Neurosci.* 20, 7782–7789.
80. Nishi A., Snyder G. L., Greengard P. (1997). Bidirectional regulation of DARPP-32 phosphorylation by dopamine. *J. Neurosci.* 17, 8147–8155.
81. Nishioka K., Tanaka R., Shimura H., Hirano K., Hatano T., Miyakawa K., et al. . (2014). Quantitative evaluation of electroconvulsive therapy for Parkinson's disease with refractory psychiatric symptoms. *J. Neural. Transm. (Vienna)* 121, 1405–1410. 10.1007/s00702-014-1212-4
82. Noyce A. J., Bestwick J. P., Silveira-Moriyama L., Hawkes C. H., Giovannoni G., Lees A. J., et al. . (2012). Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Ann. Neurol.* 72, 893–901. 10.1002/ana.23687
83. Orru M., Bakešová J., Brugarolas M., Quiroz C., Beaumont V., Goldberg S. R., et al. (2011). Striatal pre-and postsynaptic profile of adenosine A_{2A} receptor antagonists. *PLoS ONE* 6:e16088 10.1371/journal.pone.0016088

84. Petzer J. P., Petzer A. (2015). Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease. *Curr. Med. Chem.* 22, 975–988. 10.2174/0929867322666141215160015
85. Petzer J. P., Steyn S., Castagnoli K. P., Chen J. F., Schwarzschild M. A., Van der Schyf C. J., et al. . (2003). Inhibition of monoamine oxidase B by selective adenosine A_{2A} receptor antagonists. *Bioorg. Med. Chem.* 11, 1299–1310. 10.1016/S0968-0896(02)00648-X
86. Pezzoli G., Cereda E. (2013). Exposure to pesticides or solvents and risk of Parkinson disease. *Neurology* 80, 2035–2041. 10.1212/WNL.0b013e318294b3c8
87. Picelli A., Varalta V., Melotti C., Zatezalo V., Fonte C., Amato S., et al. . (2016). Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson's disease: a pilot, single-blind, randomized controlled trial. *Funct. Neurol.* 31, 25–31. 10.11138/FNeur/2016.31.1.025
88. Pinna A., Bonaventura J., Farré D., Sánchez M., Simola N., Mallol J., et al. (2014). L-DOPA disrupts adenosine A_{2A}-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. *Exp. Neurol.* 253, 180–191. 10.1016/j.expneurol.2013.12.021
89. Pinna A., Ko W. K., Costa G., Tronci E., Fidalgo C., Simola N., et al. . (2016). Antidyskinetic effect of A_{2A} and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease. *Mov. Disord.* 31, 501–511. 10.1002/mds.26475
90. Pinna A., Pontis S., Borsini F., Morelli M. (2007). Adenosine A_{2A} receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. *Synapse* 61, 606–614. 10.1002/syn.20410
91. Pollack A. E., Fink J. S. (1995). Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. *Neuroscience* 68, 721–728. 10.1016/0306-4522(95)00168-I
92. Postuma R. B., Lang A. E., Munhoz R. P., Charland K., Pelletier A., Moscovich M., et al. . (2012). Caffeine for treatment of Parkinson disease: a randomized controlled trial. *Neurology* 79, 651–658. 10.1212/WNL.0b013e318263570d
93. Ralevic V., Burnstock G. (1998). Receptors for purines and pyrimidines. *Pharmacol. Rev.* 50, 413–492.
94. Redenšek S., Trošt M., Dolžan V. (2017). Genetic determinants of parkinson's disease: can they help to stratify the patients based on the underlying molecular defect? *Front. Aging Neurosci.* 9:20. 10.3389/fnagi.2017.00020
95. Ross G. W., Abbott R. D., Petrovitch H., Morens D. M., Grandinetti A., Tung K. H., et al. . (2000). Association of coffee and caffeine intake with the risk of Parkinson disease. *JAMA* 283, 2674–2679. 10.1001/jama.283.20.2674
96. Sadek A. R., Knight G. E., Burnstock G. (2011). Electroconvulsive therapy: a novel hypothesis for the involvement of purinergic signalling. *Purinergic Signal.* 7, 447–452. 10.1007/s11302-011-9242-y
97. Salamone J. D., Collins-Praino L. E., Pardo M., Podurriel S. J., Baqi Y., Müller C. E., et al. (2013). Conditional neural knockout of the adenosine A_{2A} receptor and pharmacological A_{2A} antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor. *Eur. Neuropsychopharmacol.* 23, 972–977. 10.1016/j.euroneuro.2012.08.004
98. Scott L., Dawson V. L., Dawson T. M. (2017). Trumping neurodegeneration: targeting common pathways regulated by autosomal recessive Parkinson's disease genes. *Exp. Neurol.* 298(Pt B), 191–201. 10.1016/j.expneurol.2017.04.008

99. Shanahan J., Morris M. E., Bhriain O. N., Volpe D., Lynch T., Clifford A. M. (2017). Dancing for Parkinson Disease: a randomized trial of irish set dancing compared with usual care. *Arch. Phys. Med. Rehabil.* 98, 1744–1751. 10.1016/j.apmr.2017.02.017
100. Sharma J. C., Lewis A. (2017). Weight in Parkinson's Disease: phenotypical significance. *Int. Rev. Neurobiol.* 134, 891–919. 10.1016/bs.irn.2017.04.011
101. Shen H., Luo Y., Yu S. J., Wang Y. (2011). Enhanced neurodegeneration after a high dose of methamphetamine in adenosine A3 receptor null mutant mice. *Neuroscience* 194, 170–180. 10.1016/j.neuroscience.2011.08.013
102. Shen X., Yang H., Wu Y., Zhang D., Jiang H. (2017). Association of *Helicobacter pylori* infection with Parkinson's diseases: a meta-analysis. *Helicobacter* 22:e12398. 10.1111/hel.12398
103. Shin H. K., Lee S. W., Choi B. T. (2017). Modulation of neurogenesis via neurotrophic factors in acupuncture treatments for neurological diseases. *Biochem Pharmacol.* 141, 132–142. 10.1016/j.bcp.2017.04.029
104. Simola N., Fenu S., Baraldi P. G., Tabrizi M. A., Morelli M. (2006). Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. *J. Neurol. Sci.* 248, 48–52. 10.1016/j.jns.2006.05.038
105. Song L., Kong M., Ma Y., Ba M., Liu Z. (2009). Inhibitory effect of 8-(3-chlorostyryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats. *Brain Res.* 1276, 171–179. 10.1016/j.brainres.2009.04.028
106. Sonsalla P. K., Wong L. Y., Harris S. L., Richardson J. R., Khobahy I., Li W., et al. (2012). Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease. *Exp. Neurol.* 234, 482–487. 10.1016/j.expneurol.2012.01.022
107. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M., Goedert M. (1998). Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. *Proc. Natl. Acad. Sci. U.S.A.* 95, 6469–6473. 10.1073/pnas.95.11.6469 [PMC free article] [PubMed]
108. Stacy M., Silver D., Mendis T., Sutton J., Mori A., Chaikin P., et al. (2008). A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. *Neurology* 70, 2233–2240. 10.1212/01.wnl.0000313834.22171.17
109. Stocchi F., Rascol O., Hauser R. A., Huyck S., Tzontcheva A., Capece R., et al. (2017). Randomized trial of pramipexole, given as monotherapy, in patients with early Parkinson disease. *Neurology* 88, 2198–2206. 10.1212/WNL.0000000000004003
110. Strömberg I., Popoli P., Müller C. E., Ferré S., Fuxe K. (2000). Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A_{2A} receptors in dopamine D₂ receptor regulation in the rat dopamine-denervated striatum. *Eur. J. Neurosci.* 12, 4033–4037. 10.1046/j.1460-9568.2000.00288.x
111. Suarez-Cedeno G., Suescun J., Schiess M. C. (2017). Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease. *Parkinsons. Dis.* 2017:9358153. 10.1155/2017/9358153
112. Svenningsson P., Fourreau L., Bloch B., Fredholm B. B., Gonon F., Le Moine C. (1999). Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons. *Neuroscience* 89, 827–837. 10.1016/S0306-4522(98)00403-5
113. Tanganelli S., Sandager Nielsen K., Ferraro L., Antonelli T., Scheel-Krüger J. (2004). Striatal plasticity at the network level. Focus on adenosine A_{2A} and

- D₂ interactions in models of Parkinson's Disease. *Parkinsonism Relat. Disord.* 10, 273–280. 10.1016/j.parkreldis.2004.02.015
114. Tomiyama M., Kimura T., Maeda T., Tanaka H., Kannari K., Baba M. (2004). Upregulation of striatal adenosine A_{2A} receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. *Synapse* 52, 218–222. 10.1002/syn.20011
 115. Tozzi A., de Iure A., Di Filippo M., Tantucci M., Costa C., Borsini F., et al. (2011). The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A_{2A} receptor interaction in the striatum: implications for Parkinson's disease. *J. Neurosci.* 31, 1850–1862. 10.1523/JNEUROSCI.4082-10.2011
 116. Trifilieff P., Rives M. L., Urizar E., Piskorowski R. A., Vishwasrao H. D., Castrillon J., et al. (2011). Detection of antigen interactions *ex vivo* by proximity ligation assay: endogenous dopamine D₂-adenosine A_{2A} receptor complexes in the striatum. *Biotechniques* 51, 111–118. 10.2144/000113719
 117. Tronci E., Simola N., Borsini F., Schintu N., Frau L., Carminati P., et al. (2007). Characterization of the antiparkinsonian effects of the new adenosine A_{2A} receptor antagonist ST1535: acute and subchronic studies in rats. *Eur. J. Pharmacol.* 566, 94–102. 10.1016/j.ejphar.2007.03.021
 118. Uchida S., Kadowaki-Horita T., Kanda T. (2014). Effects of the adenosine A_{2A} receptor antagonist on cognitive dysfunction in Parkinson's disease. *Int. Rev. Neurobiol.* 119, 169–189. 10.1016/B978-0-12-801022-8.00008-8
 119. Van der Mark M., Brouwer M., Kromhout H., Nijssen P., Huss A., Vermeulen R. (2012). Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. *Environ. Health Perspect.* 120, 340–347. 10.1289/ehp.1103881
 120. Van der Walt M. M., Terre'Blanche G., Petzer A., Petzer J. P. (2015). The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylpthalimide analogues. *Bioorg. Chem.* 59, 117–123. 10.1016/j.bioorg.2015.02.005
 121. Villar-Cheda B., Sousa-Ribeiro D., Rodriguez-Pallares J., Rodriguez-Perez A. I., Guerra M. J., Labandeira-Garcia J. L. (2009). Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. *J. Cereb. Blood Flow Metab.* 29, 230–234. 10.1038/jcbfm.2008.127
 122. Volkow N. D., Wang G. J., Logan J., Alexoff D., Fowler J. S., Thanos P. K., et al. (2015). Caffeine increases striatal dopamine D₂/D₃ receptor availability in the human brain. *Transl. Psychiatry* 5, e549. 10.1038/tp.2015.46
 123. Vortherms T. A., Watts V. J. (2004). Sensitization of neuronal A_{2A} adenosine receptors after persistent D₂ dopamine receptor activation. *J. Pharmacol. Exp. Ther.* 308, 221–227. 10.1124/jpet.103.057083
 124. Watanabe H., Ikeda M., Watanabe K. (1981). Properties of rotational behaviour produced by methylxanthine derivatives in mice with unilateral striatal 6-hydroxydopamine-induced lesions. *J. Pharmacobiodyn.* 4, 301–307. 10.1248/bpb1978.4.301
 125. Xu K., Di Luca D. G., Orrú M., Xu Y., Chen J. F., Schwarzschild M. A. (2016). Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A_{2A} receptors. *Neuroscience.* 322, 129–137. 10.1016/j.neuroscience.2016.02.035
 126. Yang M., Soohoo D., Soelaiman S., Kalla R., Zablocki J., Chu N., et al. (2007). Characterization of the potency, selectivity, and pharmacokinetic profile for

- six adenosine A_{2A} receptor antagonists. Naunyn Schmiedebergs. Arch. Pharmacol. 375, 133–144. 10.1007/s00210-007-0135-0
127. Yu L., Schwarzschild M. A., Chen J. F. (2006). Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neurosci. Lett. 393, 31–35. 10.1016/j.neulet.2005.09.036

